

RECEIVED

ALIG 2 0 2002

TECH CENTER 1600/2900

FILE NO. A34084-PCT-USA-A/ 066031.0147 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Kaempfer et al.

Serial No.

09/801,371

Examiner:

Whiteman, B.

Filed

March 7, 2001

Group Art Unit:

1635

For

REGULATION OF GENE EXPRESSION THROUGH

MANIPULATION OF mRNA SPLICING AND ITS USES

RESPONSE TO RESTRICTION REQUIREMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231

August 7, 2002

Date of Deposit

Alicia A. Russo

46,192

Attorney Name

PTO Registration No.

Signatura

August 7, 2002

Date of Signature

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office Communication dated April 9,

2002. Applicants request a three-month extension of time and enclose the fee required under 37

C.F.R. §1.17(a)(3). Applicants respectfully request reconsideration of the above-identified

application in light of the amendments and remarks presented herein.

NY02:395676.1

FILE NO. A34084-PCT-USA-A/ 066031.0147 PATENT

IN THE CLAIMS

RECEIVED

Please cancel claims 32-46 and 50 without prejudice.

AUG 2 0 2002

TECH CENTER 1600/2900

REMARKS

This paper is being filed in response to the Office Communication dated April 9, 2002. Applicants request a three-month extension of time and enclose the fee required under 37 C.F.R. §1.17(a)(3). Applicants respectfully request reconsideration of the above-identified application in light of the amendments and remarks presented herein.

Claims 1-50 are pending. Claims 32-46 and 50 have been cancelled.

The Examiner has stated that the claims of the present application contains distinct inventions, which he has divided into the following six groups:

Group I: Claims 1-31 and 47-49, drawn to a cis-acting nucleotide sequence;

Group II: Claims 32-33 and 50 drawn to a method of producing a recombinant enzyme, hormone, cytokine, structural protein, or industrially or agriculturally applicable protein (an election of one of an enzyme, hormone, cytokine, etc., is further required if Group II is selected);

Group III: Claims 34-35, 37-38 and 43-45, drawn to a method of regulating gene expression at the mRNA splicing level;

Group IV: Claims 34, 36, and 43-45, drawn to a method of regulating gene expression at the mRNA splicing level (differs from Group III in step (a) due to the use of a trans-dominant negative mutant of PKRα6);

Group V: Claims 34, 36, and 43-45, drawn to a method of regulating gene expression at the mRNA splicing level (differ from Groups III and IV in step (a) due to the use of a vector expressing viral proteins); and

Group VI: Claims 43, 44 and 46, drawn to an ex vivo method of providing a therapeutic protein to a mammal.

The Examiner contends that Applicants must elect one group to be examined in the present application. In response, Applicants elect to pursue the claims of Group I (claims 1-31 and 47-49) without traverse and without prejudice to pursuing the cancelled claims of Groups II-VI in one or more divisional applications.

FILE NO. A34084-PCT-USA-A/ 066031.0147 PATENT

Applicants have enclosed the fee for a three-month extension of time as required under 37 C.F.R. §1.17(a)(3). Applicants do not believe that any additional fee is required for this filing. Nevertheless, the Commissioner is hereby authorized to charge any fees required for this submission not otherwise enclosed herewith to Deposit Account No. 02-4377. Two copies of this page are enclosed.

Respectfully submitted,

August 7, 2002

Rochelle K. Seide

Patent Office Reg. No. 32,300

Alicia A. Russo

Patent Office, Reg. No. 46,192

Attorneys for Applicants BAKER BOTTS, L.L.P. 30 Rockefeller Plaza New York, NY 10112 (212) 408-2500

BAKER BOTTS LLP



#18 1635\$*
RECEIVED

· · · · · · · · · · · · · · · · · · ·		Application Number	09/801,371
TRANSMITT	'AL	Filing Date	March 7, 2001
FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission 8		First Named Inventor	Raymond Kaempfer
		Group Art Unit	1635
		Examiner Name	Whiteman, Brian A.
		Attorney Docket Number	404004 DOT 1104 A
		<u> </u>	all that apply)
Fee Attached mendment / Reply After Final Affidavits/declaration(s) tension of Time Request press Abandonment Request formation Disclosure Statement ertified Copy of Priority cument(s) esponse to Missing Parts/ complete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing Licensir Petition Provision Power of Change Address Termina Reques	to Convert to a enal Application of Attorney, Revocation of Correspondence	Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below):
BakerBotts LLP 30 Rockefeller Pla New York, NY 101 August 7, 2002	aza 112 Lesso	Att Name: PTO Reg:	Alicia A. Russo 46,192

Signature

August 7, 2002 Date

BAKER BOTTS LLP

RECEIVED

AUG 2 0 2002 C mpl t if Known FEE TRANSMITTAL TECH CENTER 600/2900 **Application Number** 09/801,371 March 7, 2001 Filing Date for FY 2002 AUG 1 3 2002 Raymond Kaempfer First Named Inventor Whiteman, Brian A. **Examiner Name** Patent fees are subject to annual revision. 1635 **Group Art Unit** (\$) 460 TOTAL AMOUNT OF PAYMENT A34084-PCT-USA-A Attorney Docket No.

METHOD OF PAYMENT		F	EE CALCULATION (continued)	
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDI	TIONAL FI	EES	
Denosit		Large Small Entity Entity		
Account Number 02-4377	Fed	Fee	•	Fee Paid
Deposit Account Baker Botts LLP	(\$) 130	(\$) 65	Surcharge - late filing fee or oath	
Charge Any Additional Fee Required	50	25	Surcharge - late provisional filing fee or cover sheet	
Under 37 CFR 1.16 and 1.17 Applicant claims small entity status.	130	130	Non-English specification	
See 37 CFR 1.27	2,520	2,520	For filing a request for ex parte reexamination	1
2. Payment Enclosed: Check Credit card Money Other	920	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	1,840	1,840	* Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	110	55	Extension for reply within first month	
Large Entity Small Entity	400	200	Extension for reply within second month	
Fee Fee Description	920	460	Extension for reply within third month	460
(\$) (\$) Fee Paid	1,440	720	Extension for reply within fourth month	
740 370 Utility filing fee 330 165 Design filing fee	1,960	980	Extension for reply within fifth month	
510 255 Plant filing fee	320	160	Notice of Appeal	
740 370 Reissue filing fee	320	160	Filing a brief in support of an appeal	
160 80 Provisional filing fee	280	140	Request for oral hearing	
	1,510	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$) 0	110	55	Petition to revive - unavoidable	
2. EXTRA CLAIM FEES	1,280	640	Petition to revive - unintentional	
Fee from Ext <u>ra Claims below</u> Fee Pai	d 1,280	640	Utility issue fee (or reissue)	
Total Claims 20 •• = 0		230	Design issue fee	
ndependent - 3 = 0 x = 0	620	310	Plant issue fee	
Multiple Dependent =	130	130	Petitions to the Commissioner	
	50	50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Description	180	180	Submission of Information Disclosure Stmt	
(\$) (\$) 18 9 Claims in excess of 20	40	40	Recording each patent assignment per property (times number of properties)	
84 42 Independent claims in excess of 3	740	370	Filing a submission after final rejection	
280 140 Multiple dependent claim, if not paid			(37 CFR § 1.129(a))	
84 42 ** Reissue independent claims over original patent	740	370	For each additional invention to be examined (37 CFR § 1.129(b))	
18 9 ** Reissue claims in excess of 20	740	370	Request for Continued Examination (RCE)	
and over original patent	900	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 0	Other fee (s	pecify)		
**or number previously paid, if greater; For Reissues, see above	*Reduced t	y Basic Filing	Fee Paid SUBTOTAL (3) (\$) 46	0

SUBMITTED BY

Name (PrintlType)
Alicia A. Russo
Registration No. (Attorney/Agent)
Alicia A. Russo
Date
August 7, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

BAKER BOTTS LLP

Attorney Docket Number: A34084-PCT-USA-A

Title:	REGULATION OF GENE EXPRESSION THROUGH MANIPULATION OF mRNA SPLICING AND ITS USES
Use Space 1	Below for Additional Information:
*	